TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,293,598 | -55.4% | 4,395,257 | -23.3% | 0.00% | -60.0% |
| Q2 2023 | $88,053,289 | -10.4% | 5,732,636 | +31.2% | 0.01% | -16.7% |
| Q1 2023 | $98,233,554 | -44.7% | 4,367,877 | -48.3% | 0.01% | +20.0% |
| Q4 2022 | $177,662,450 | +111.2% | 8,448,048 | +147.5% | 0.01% | 0.0% |
| Q3 2022 | $84,107,000 | -3.8% | 3,413,415 | -5.4% | 0.01% | 0.0% |
| Q2 2022 | $87,402,000 | +14.6% | 3,607,165 | +21.9% | 0.01% | +25.0% |
| Q1 2022 | $76,263,000 | -14.9% | 2,959,361 | +2.5% | 0.00% | 0.0% |
| Q4 2021 | $89,615,000 | +32.8% | 2,887,077 | +3.8% | 0.00% | 0.0% |
| Q3 2021 | $67,471,000 | +33.9% | 2,782,323 | -19.4% | 0.00% | +33.3% |
| Q2 2021 | $50,392,000 | -17.3% | 3,453,859 | +41.6% | 0.00% | 0.0% |
| Q1 2021 | $60,915,000 | – | 2,439,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |